UCSF Dermatology Grand Rounds - 15 May 2024
Wednesday, May 15 at 8:10 am
-
10:15 am
Add to Calendar
2024-05-15 15:10:00
2024-05-15 17:15:00
UCSF Dermatology Grand Rounds - 15 May 2024
GRAND ROUNDS AND PATIENT VIEWINGZoom
Resident Expert TalksOlivia Ware, MD, Chief, PGY-4 Resident, Department of Dermatology, UCSF and Kira Seiger, MD, MBA, PGY-4 Resident, Department of Dermatology, UCSF
Private Equity and Health Equity: Considerations for Access and Costs in the Changing Landscape of Dermatology Practice
Kira Seiger, MD, MBA, Resident Physician, Department of Dermatology, UCSF
1. Understand current and historical investment presence in care delivery organizations, particularly dermatology practices
2. Discuss implications for healthcare access (utilization, wait times, insurance acceptance), costs, and spending
Speaker Disclosures:
Kira Seiger, MD, MBA and Olivia Ware, MD have stated that they have no financial relationships to disclose.
Planner Disclosures:
Ilona Frieden, MD has disclosed that she is a consultant for Venthera Bridgebio, Data Safety Monitoring Advisory Board for Pfizer, and Data Reviewer on the NCT02913612 Pediatric Trials
Network-NIH Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) (TIM01).
Kelly Cordoro, MD, Hunter Shain, PhD and Amanda Twigg, MD have stated they have no relationships to disclose.
Department Of Dermatology
Laura.Harrison@ucsf.edu
America/Los_Angeles
public
GRAND ROUNDS AND PATIENT VIEWING
Zoom
Resident Expert Talks
Olivia Ware, MD, Chief, PGY-4 Resident, Department of Dermatology, UCSF and Kira Seiger, MD, MBA, PGY-4 Resident, Department of Dermatology, UCSF
Private Equity and Health Equity: Considerations for Access and Costs in the Changing Landscape of Dermatology Practice
Kira Seiger, MD, MBA, Resident Physician, Department of Dermatology, UCSF
1. Understand current and historical investment presence in care delivery organizations, particularly dermatology practices
2. Discuss implications for healthcare access (utilization, wait times, insurance acceptance), costs, and spending
Speaker Disclosures:
Kira Seiger, MD, MBA and Olivia Ware, MD have stated that they have no financial relationships to disclose.
Planner Disclosures:
Ilona Frieden, MD has disclosed that she is a consultant for Venthera Bridgebio, Data Safety Monitoring Advisory Board for Pfizer, and Data Reviewer on the NCT02913612 Pediatric Trials
Network-NIH Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) (TIM01).
Kelly Cordoro, MD, Hunter Shain, PhD and Amanda Twigg, MD have stated they have no relationships to disclose.